Skip to main content

Table 1 Patient characteristics

From: Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B

Variables

HBeAg (-) (n=39)

HBeAg (+) (n=55)

P value

no.

%

no.

%

 

Age, <40/40-59/60≤

7/22/10

18/56/26

22/23/10

40/42/18

0.07

Age (y/o)

50.0 ± 11.8

44.3 ± 14.5

0.03

Gender, female/male

11/28

28/72

18/37

33/67

0.7

Drug, LAM/ETV

25/14

64/36

38/17

69/31

0.7

ALT (IU/L), <100/100-199/200≤

12/16/11

31/41/28

20/13/22

36/24/40

0.19

HBV-DNA (Log copy/mL), <6/6-7.6/7.6<

11/22/6

28/56/15

4/20/31

7/36/56

0.001

Genotype*, B/C

5/26

16/84

1/37

3/97

0.07

HBsAg (IU/mL)*, <1000/1000-10000/10000≤

7/11/5

30/48/22

3/9/8

15/45/40

0.09

Histology (METAVIR Staging)*, 1/2/3

13/8/6

48/30/22

11/13/7

35/42/23

0.6

Histology (METAVIR Grading)*, 1/2/3

7/17/3

26/63/11

8/15/8

26/48/26

0.3

  1. *Data were not available in some patients